2013

Creutzberg, C. L., H. C. Kitchener, M. J. Birrer, F. Landoni, K. H. Lu, M. Powell, C. Aghajanian, R. Edmondson, P. J. Goodfellow, M. Quinn, H. B. Salvesen, G. Thomas and G. E. C. C. T. P. Meeting (2013). "Gynecologic Cancer InterGroup (GCIG) Endometrial Cancer Clinical Trials Planning Meeting: taking endometrial cancer trials into the translational era." Int J Gynecol Cancer 23(8): 1528-1534.

Delahanty, R. J., Y. B. Xiang, A. Spurdle, A. Beeghly-Fadiel, J. Long, D. Thompson, I. Tomlinson, H. Yu, D. Lambrechts, T. Dork, M. T. Goodman, Y. Zheng, H. B. Salvesen, P. P. Bao, F. Amant, M. W. Beckmann, L. Coenegrachts, A. Coosemans, N. Dubrowinskaja, A. Dunning, I. B. Runnebaum, D. Easton, A. B. Ekici, P. A. Fasching, M. K. Halle, A. Hein, K. Howarth, M. Gorman, D. Kaydarova, C. Krakstad, F. Lose, L. Lu, G. Lurie, T. O'Mara, R. K. Matsuno, P. Pharoah, H. Risch, M. Corssen, J. Trovik, N. Turmanov, W. Wen, W. Lu, Q. Cai, W. Zheng and X. O. Shu (2013). "Polymorphisms in inflammation pathway genes and endometrial cancer risk." Cancer Epidemiol Biomarkers Prev 22(2): 216-223.

Doufekas, K., R. Hadwin, R. Kandimalla, A. Jones, T. Mould, S. Crowe, A. Olaitan, N. Macdonald, H. Fiegl, E. Wik, H. B. Salvesen and M. Widschwendter (2013). "GALR1 methylation in vaginal swabs is highly accurate in identifying women with endometrial cancer." Int J Gynecol Cancer 23(6): 1050-1055.

Garcia-Dios, D. A., D. Lambrechts, L. Coenegrachts, I. Vandenput, A. Capoen, P. M. Webb, K. Ferguson, Anecs, L. A. Akslen, B. Claes, I. Vergote, P. Moerman, J. Van Robays, J. Marcickiewicz, H. B. Salvesen, A. B. Spurdle and F. Amant (2013). "High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma." Gynecol Oncol 128(2): 327-334.

Haldorsen, I. S., R. Gruner, J. A. Husby, I. J. Magnussen, H. M. Werner, O. O.

Salvesen, L. Bjorge, I. Stefansson, L. A. Akslen, J. Trovik, T. Taxt and H. B. Salvesen (2013). "Dynamic contrast-enhanced MRI in endometrial carcinoma identifies patients at increased risk of recurrence." Eur Radiol 23(10): 2916-2925.

Haslene-Hox, H., E. Oveland, K. Woie, H. B. Salvesen, H. Wiig and O. Tenstad (2013). "Increased WD-repeat containing protein 1 in interstitial fluid from ovarian carcinomas shown by comparative proteomic analysis of malignant and healthy gynecological tissue." Biochim Biophys Acta 1834(11): 2347-2359.

Herfindal, L., G. Nygaard, R. Kopperud, C. Krakstad, S. O. Doskeland and F. Selheim (2013). "Off-target effect of the Epac agonist 8-pCPT-2'-O-Me-cAMP on P2Y12 receptors in blood platelets." Biochem Biophys Res Commun 437(4): 603-608.

Jones, A., A. E. Teschendorff, Q. Li, J. D. Hayward, A. Kannan, T. Mould, J. West, M. Zikan, D. Cibula, H. Fiegl, S. H. Lee, E. Wik, R. Hadwin, R. Arora, C. Lemech, H. Turunen, P. Pakarinen, I. J. Jacobs, H. B. Salvesen, M. K. Bagchi, I. C. Bagchi and M. Widschwendter (2013). "Role of DNA methylation and epigenetic silencing of HAND2 in endometrial cancer development." PLoS Med 10(11): e1001551.

Njolstad, T. S., H. Engerud, H. M. Werner, H. B. Salvesen and J. Trovik (2013). "Preoperative anemia, leukocytosis and thrombocytosis identify aggressive endometrial carcinomas." Gynecol Oncol 131(2): 410-415.

Raeder, M. B., E. Birkeland, J. Trovik, C. Krakstad, S. Shehata, S. Schumacher, T. I. Zack, A. Krohn, H. M. Werner, S. E. Moody, E. Wik, I. M. Stefansson, F. Holst, A. M. Oyan, P. Tamayo, J. P. Mesirov, K. H. Kalland, L. A. Akslen, R. Simon, R. Beroukhim and H. B. Salvesen (2013). "Integrated genomic analysis of the 8q24 amplification in endometrial cancers identifies ATAD2 as essential to MYC-dependent cancers." PLoS One 8(2): e54873.

Salvesen, H. B., H. M. Werner and C. Krakstad (2013). "PI3K pathway in gynecologic malignancies." Am Soc Clin Oncol Educ Book.

Trovik, J., E. Wik, H. M. Werner, C. Krakstad, H. Helland, I. Vandenput, T. S. Njolstad, I. M. Stefansson, J. Marcickiewicz, S. Tingulstad, A. C. Staff, T. E. C. s. g. MoMa, F. Amant, L. A. Akslen and H. B. Salvesen (2013). "Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial." Eur J Cancer 49(16): 3431-3441.

Werner, H. M., A. Berg, E. Wik, E. Birkeland, C. Krakstad, K. Kusonmano, K. Petersen, K. H. Kalland, A. M. Oyan, L. A. Akslen, J. Trovik and H. B. Salvesen (2013). "ARID1A loss is prevalent in endometrial hyperplasia with atypia and low-grade endometrioid carcinomas." Mod Pathol 26(3): 428-434.

Werner, H. M., J. Trovik, J. Marcickiewicz, S. Tingulstad, A. C. Staff, M. E. Engh, K. Oddenes, J. A. Rokne, J. Tjugum, M. S. Lode, F. Amant and H. B. Salvesen (2013). "A discordant histological risk classification in preoperative and operative biopsy in endometrial cancer is reflected in metastatic risk and prognosis." Eur J Cancer 49(3): 625-632.

Wik, E., E. Birkeland, J. Trovik, H. M. Werner, E. A. Hoivik, S. Mjos, C. Krakstad, K. Kusonmano, K. Mauland, I. M. Stefansson, F. Holst, K. Petersen, A. M. Oyan, R. Simon, K. H. Kalland, W. Ricketts, L. A. Akslen and H. B. Salvesen (2013). "High phospho-Stathmin(Serine38) expression identifies aggressive endometrial cancer and suggests an association with PI3K inhibition." Clin Cancer Res 19(9): 2331-2341.

Wik, E., M. B. Raeder, C. Krakstad, J. Trovik, E. Birkeland, E. A. Hoivik, S. Mjos, H. M. Werner, M. Mannelqvist, I. M. Stefansson, A. M. Oyan, K. H. Kalland, L. A. Akslen and H. B. Salvesen (2013). "Lack of estrogen receptor-alpha is associated with epithelial-mesenchymal transition and PI3K alterations in endometrial carcinoma." Clin Cancer Res 19(5): 1094-1105.